| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/24/2011 | US20110044901 Novel compounds |
| 02/24/2011 | US20110044893 Vascular targets for detecting, imaging and treating neoplasia or neovasculature |
| 02/24/2011 | DE10251709C5 Screening-Verfahren für Wirkstoffe zur Stimulierung der humanen beta-Defensine vom Typ 2 und/oder Typ 3 Screening method for agents to stimulate the human beta-defensins type 2 and / or type 3 |
| 02/24/2011 | DE102009037551A1 Cyclosporinderivate Cyclosporin derivatives |
| 02/24/2011 | DE102005062440B4 Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen Protein-based carrier system to overcome resistance of tumor cells |
| 02/24/2011 | CA2771429A1 Use of mimotopes of alpha-synuclein epitopes for treating lewy body diseases |
| 02/24/2011 | CA2771261A1 Apparatus and process for generating and harvesting adult stem cells and fluid associated with it from skin and omentum for medical, cosmetic, and veterinary use |
| 02/24/2011 | CA2771232A1 Purification of vwf for increased removal of non-lipid enveloped viruses |
| 02/24/2011 | CA2770609A1 Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders |
| 02/24/2011 | CA2770185A1 Fast acting snare-cleaving enzymes |
| 02/24/2011 | CA2769409A1 Use of nkg2d inhibitors for treating cardiovascular and metabolic diseases, such as type 2 diabetes |
| 02/24/2011 | CA2769407A1 Mimotopes of hiv and uses thereof |
| 02/24/2011 | CA2768640A1 Apolipoprotein l-i variants and their use |
| 02/23/2011 | EP2287337A2 Identification of surface-associated Antigenes used for the diagnosis and therapy of tumours |
| 02/23/2011 | EP2287319A1 Medical preparations for the treatment of alpha-galactosidase a deficiency |
| 02/23/2011 | EP2287309A1 Novel expression vectors containing accessory molecule ligand genes and their use for immunomodulation and treatment of malignancies and autoimmune disease |
| 02/23/2011 | EP2287306A1 RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
| 02/23/2011 | EP2287305A1 RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
| 02/23/2011 | EP2287192A1 Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| 02/23/2011 | EP2287186A1 Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer |
| 02/23/2011 | EP2287184A2 Novel insulin derivatives |
| 02/23/2011 | EP2287183A1 Mutants PF4 polypeptides exhibiting an increased anti-angiogenic activity |
| 02/23/2011 | EP2287182A2 Differential in tumour gene products and use of same |
| 02/23/2011 | EP2287181A2 Differential in tumour gene products and use of same |
| 02/23/2011 | EP2287175A2 Novel chemokine binding peptides capable of modulating the biological activity of chemokines |
| 02/23/2011 | EP2286847A1 Formulations of hyaluronic acid for delivery of osteogenic proteins |
| 02/23/2011 | EP2286843A2 Compounds for targeting endothelial cells |
| 02/23/2011 | EP2286840A2 Treatment of obesity and related diseases |
| 02/23/2011 | EP2286839A2 Treatment of obesity and related diseases |
| 02/23/2011 | EP2286838A2 Treatment of obesity and related disorders |
| 02/23/2011 | EP2286837A2 Treatment of obesity and obesity related diseases |
| 02/23/2011 | EP2286836A1 Immunostimulating agent |
| 02/23/2011 | EP2286834A2 Use of skin penetration enhancers and barrier disruption agents to enhance transcutaneous immune response |
| 02/23/2011 | EP2286831A1 A method of inducing a CTL response |
| 02/23/2011 | EP2286829A1 Drug, dental material, and screening method |
| 02/23/2011 | EP2286828A1 Ameliorating agent for neurogenic pain |
| 02/23/2011 | EP2286827A1 Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases |
| 02/23/2011 | EP2286826A2 Treatment of tumor metastase and cancer |
| 02/23/2011 | EP2286825A2 Melanocortin receptor ligands |
| 02/23/2011 | EP2286824A1 Non-covalent crosslinking agent for collagen |
| 02/23/2011 | EP2286804A1 A method of treating degenerative disc disease |
| 02/23/2011 | EP2286791A1 Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents, preferably a GnRH |
| 02/23/2011 | EP2285989A2 Novel targets for regulation of angiogenesis |
| 02/23/2011 | EP2285828A1 Polypeptides involved in the neuroregeneration-promoting properties of olfactory ensheathing glia |
| 02/23/2011 | EP2285826A1 Anti-angiogenic compositions and therapeutic applications thereof |
| 02/23/2011 | EP2285825A1 Method of forming non-immunogenic hydrophobic protein nanoparticles and uses therefor |
| 02/23/2011 | EP2285420A2 Polyelectrolyte with positive net charge for use as medicament and diagnostic for cancer |
| 02/23/2011 | EP2285418A1 Stimuli-responsive hydrogel |
| 02/23/2011 | EP2285416A2 Conjugates for the treatment of mesothelioma |
| 02/23/2011 | EP2285412A1 Formulations of peg-functionalised serine proteases with high concentrations of an aromatic preservative |
| 02/23/2011 | EP2285402A2 Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions |
| 02/23/2011 | EP2285401A1 Low viscosity compositions comprising a pegylated gla-domain containing protein |
| 02/23/2011 | EP2285400A2 Treatment of bleeding with low half-life fibrinogen |
| 02/23/2011 | EP2285399A2 Egf-a domain-mediated modulation of pcsk9 for treating lipid disorders |
| 02/23/2011 | EP2285398A2 Methods and compositions for the treatment of obesity |
| 02/23/2011 | EP2285397A2 Immunotherapies employing self-assembling vaccines |
| 02/23/2011 | EP2285396A1 Novel dual targeting antitumoural conjugates |
| 02/23/2011 | EP2285395A2 Molecules interfering with binding of calbindin to inositol monophosphatase for the treatment of mood disorders |
| 02/23/2011 | EP2285364A2 Therapeutic replenishment and enrichment of ocular surface lubrication |
| 02/23/2011 | EP2285361A2 Therapeutic calcium phosphate particles and methods of making and using same |
| 02/23/2011 | EP2285359A2 Solid pharmaceutical formulation with delayed release |
| 02/23/2011 | EP2285349A1 Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer |
| 02/23/2011 | EP2285244A1 Sialic acid to support the immune system in the elderly |
| 02/23/2011 | EP2175834B1 Glp-1-fc fusion protein formulation |
| 02/23/2011 | EP1976553B1 Compositions and methods for oxalate reduction |
| 02/23/2011 | EP1819353B1 Composition for proteasome inhibition |
| 02/23/2011 | EP1524998B1 Stable aqueous pharmaceutical composition comprising erythropoietin |
| 02/23/2011 | EP1268096B2 Extrusion die |
| 02/23/2011 | EP1237920B1 A novel method to produce human natural interferon-alpha |
| 02/23/2011 | EP1135504B1 Human ubiquitin ligase e3 for the modulation of nf-kappa b |
| 02/23/2011 | EP1113819B1 Antibody directed enzyme prodrug therapy (adept) with glucuronidase |
| 02/23/2011 | EP0972024B1 A tumor suppressor designated ts10q23.3 |
| 02/23/2011 | CN1934252B Thrombin derivatives and medicinal composition containing the same |
| 02/23/2011 | CN1655802B Bioadhesive directed somatic cell therapy |
| 02/23/2011 | CN101981190A Toxin of the spider phoneutria nigriventer for treatment of erectile dysfunction |
| 02/23/2011 | CN101981187A Partial peptide of Survivin presented on MHC class II molecule and use thereof |
| 02/23/2011 | CN101981060A Low-molecular-weight substance derived from maitake mushroom and having immunostimulating activity and anti-tumor activity |
| 02/23/2011 | CN101981050A 新的凝血因子抑制剂 New clotting factor inhibitors |
| 02/23/2011 | CN101981048A A method of purifying a peptide |
| 02/23/2011 | CN101980719A Heteroaryl-containing tripeptide HCV serine protease inhibitors |
| 02/23/2011 | CN101980718A Therapeutic peptidomimetic macrocycles |
| 02/23/2011 | CN101980717A Use melanocortins to treat insulin sensitivity |
| 02/23/2011 | CN101980699A Liquid and freeze dried formulations |
| 02/23/2011 | CN101980017A Anti-TNF antibodies, compositions, methods and uses |
| 02/23/2011 | CN101979652A Mactra quadrangularis protein polypeptide with antioxidant activity and preparation method and application thereof |
| 02/23/2011 | CN101979594A Influenza virus hemagglutinin fusion peptide-containing targeted recombinant molecule gene, protein encoded thereby and application thereof |
| 02/23/2011 | CN101979591A Method for producing human lysozyme by using rice as bioreactor |
| 02/23/2011 | CN101979572A Preparation for South China Sea conus striatus toxin S4.3 and application |
| 02/23/2011 | CN101979409A Scorpion venom polypeptide for promoting cell proliferation, preparation method and medicinal application thereof |
| 02/23/2011 | CN101979403A Novel broad caspase inhibitor and preparation method and application thereof |
| 02/23/2011 | CN101979402A Marine cyclic peptide compound and preparation method and use thereof |
| 02/23/2011 | CN101979093A Composition comprising polypeptide-drug substance and other poorly absorbed active ingredient and its use |
| 02/23/2011 | CN101979090A Medicament for treating tumors |
| 02/23/2011 | CN101979088A Medicament for treating cauma and empyrosis |
| 02/23/2011 | CN101979030A Chinese medicinal ointment formula and preparation method and application thereof |
| 02/23/2011 | CN101392256B Gene synthesis of wild boar alpha-interferon, vector construction and method for producing outcome |
| 02/23/2011 | CN101220092B Human keratinized cell growth factor-1 analogue preparation method and application thereof |
| 02/22/2011 | USRE42164 Hepatitis C inhibitor tri-peptides |
| 02/22/2011 | US7893297 Amorphous sodium 4-[4-chloro-2-hydroxybenzoyl)amino]butanoate |
| 02/22/2011 | US7893264 Antiviral phosphinate compounds |